Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Chad C. Bjorklund, Ph.D., Sharon Lea Aukerman, PhD, Antonia Lopez-Girona, Ph.D., Mohamad Hussein, MD, Rajesh Chopra, PhD, Isere Kuiatse, Ph.D., Deborah J. Kuhn, Ph.D., Caimiao Wei, PhD, Robert Z. Orlowski, MD, PhD

Blood (2011) 118 (21): 928.

https://doi.org/10.1182/blood.V118.21.928.928

Published: 2011

Journal Articles

Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells

Svetlana Gaidarova, Derek Mendy, Carla Heise, PhD, Sharon Lea Aukerman, PhD, Tom Daniel, Rajesh Chopra, Antonia Lopez-Girona

Blood (2010) 116 (21): 2845.

https://doi.org/10.1182/blood.V116.21.2845.2845

Published: 2010

Journal Articles

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

John C. Byrd, MD, Ian W. Flinn, MD, Khuda D. Khan, MD, Thomas J. Kipps, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Serge Guzy, PhD, Sanela Bilic, PharmD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 2837.

https://doi.org/10.1182/blood.V108.11.2837.2837

Published: 2006

Journal Articles

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

William Bensinger, MD, Sundar Jagannath, MD, Pamela S. Becker, MD, PhD, Kenneth C. Anderson, MD, Edward A. Stadtmauer, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Sanela Bilic, PharmD, Serge Guzy, PhD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD

Blood (2006) 108 (11): 3575.

https://doi.org/10.1182/blood.V108.11.3575.3575

Published: 2006

Journal Articles

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Xia Tong, MSc, Sharon Lea Aukerman, PhD, Karen Lin, BS, Natasha Aziz, PhD, Cheryl Goldbeck, BS, Georgios V. Georgakis, MD, Anas Younes, MD, Wen-Kai Weng, MD, PhD, Susan O’Brien, MD, William Wierda, MD, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD

Blood (2005) 106 (11): 2964.

https://doi.org/10.1182/blood.V106.11.2964.2964

Published: 2005

NARROW

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Email alerts

ASH Publications

American Society of Hematology

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only